The failure of two high-profile heart disease drugs has cast serious doubt on assumptions regarding genetically validated therapies. While researchers expected genetic data to reliably speed the delivery of effective treatments, these trials showed no benefit whatsoever. Discussing the implications on "The Readout LOUD" podcast, senior medical writer Matthew Herper highlighted how these setbacks complicate upcoming cardiovascular pipelines. The broader sector is simultaneously navigating additional headwinds, including ongoing safety questions for Vertex Pharmaceuticals and Novartis as well as falling shares for Alnylam.
Key points
Relying strictly on genetic validation does not guarantee the clinical efficacy of experi…: Relying strictly on genetic validation does not guarantee the clinical efficacy of experimental cardiovascular treatments.
Cardiovascular drug pipelines face renewed uncertainty following the disappointing trial…: Cardiovascular drug pipelines face renewed uncertainty following the disappointing trial results unveiled at the medical meeting.
Broader biopharma stability is experiencing strain from safety issues and growth worries…: Broader biopharma stability is experiencing strain from safety issues and growth worries that hit Alnylam's stock.
Sources checked by our analysis pipeline: 1
On this week’s episode of “The Readout LOUD”: the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest companies in the sector.
For years, it was widely believed that a deeper understanding of genetics was going to speed the development of newer and better medicines for patients with heart disease. But then came this year’s American Heart Association meeting, which was dominated by presentations of clinical trials that showed no benefit whatsoever for two drugs long thought to be genetically validated.
Joining us to help sort out this cardiovascular conundrum and what it might portend for the future of drug research is our colleague and senior medical writer Matthew Herper.
We also chat about drug safety concerns weighing on Vertex Pharmaceuticals and Novartis, and Alnylam’s stock price tumbling on growth concerns.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
Emergency personnel in southwestern Oklahoma responded early Friday morning after an aircraft returning to Childress, Texas, went down in a rural area. One person aboard was hospitalized for treatment, while state and federal authorities moved quickly to secure the scene. Investigators are working to pinpoint what caused the flight to fail while it was en route back to its base.
Emergency crews have concluded search operations at 1321 Flatbush Avenue after a catastrophic structural failure left multiple families displaced and children among the dead. Investigators are now scrutinizing an adjacent construction site to determine if neighboring ground activity played a role in the disaster. City building inspectors and police have taken control of the scene to conduct a thorough inquiry into the structural integrity of the site.
The project "Take Me Home" examines the everyday realities of caregiving through the lens of one family's personal journey. It explores how these individuals confront ongoing support challenges while actively developing practical solutions for their situation. This intimate perspective sheds light on the broader human impact and complexities embedded within family-based care.